AUTHOR=Li Xin-yu , You Jian-xiong , Zhang Lu-yu , Su Li-xin , Yang Xi-tao 

TITLE=A Novel Model Based on Necroptosis-Related Genes for Predicting Prognosis of Patients With Prostate Adenocarcinoma

JOURNAL=Frontiers in Bioengineering and Biotechnology

VOLUME=9

YEAR=2022

URL=https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2021.814813

DOI=10.3389/fbioe.2021.814813

ISSN=2296-4185

ABSTRACT=<p><bold>Background</bold>: Necroptosis is a newly recognized form of cell death. Here, we applied bioinformatics tools to identify necroptosis-related genes using a dataset from The Cancer Genome Atlas (TCGA) database, then constructed a model for prognosis of patients with prostate cancer.</p><p><bold>Methods:</bold> RNA sequence (RNA‐seq) data and clinical information for Prostate adenocarcinoma (PRAD) patients were obtained from the TCGA portal (<ext-link ext-link-type="uri" xlink:href="http://tcga-data.nci.nih.gov/tcga/" xmlns:xlink="http://www.w3.org/1999/xlink">http://tcga-data.nci.nih.gov/tcga/</ext-link>). We performed comprehensive bioinformatics analyses to identify hub genes as potential prognostic biomarkers in PRAD u followed by establishment and validation of a prognostic model. Next, we assessed the overall prediction performance of the model using receiver operating characteristic (ROC) curves and the area under curve (AUC) of the ROC.</p><p><bold>Results:</bold> A total of 5 necroptosis-related genes, namely <italic>ALOX15, BCL2, IFNA1, PYGL</italic> and <italic>TLR3</italic>, were used to construct a survival prognostic model. The model exhibited excellent performance in the TCGA cohort and validation group and had good prediction accuracy in screening out high-risk prostate cancer patients.</p><p><bold>Conclusion:</bold> We successfully identified necroptosis-related genes and constructed a prognostic model that can accurately predict 1- 3-and 5-years overall survival (OS) rates of PRAD patients. Our riskscore model has provided novel strategy for the prediction of PRAD patients’ prognosis.</p>